Cytokinetics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.About CYTK
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.
CYTK Key Statistics
CYTK News
BofA raised the firm’s price target on Cytokinetics (CYTK) to $52 from $45 and keeps a Neutral rating on the shares. The ESC conference “was a win for the compa...
In late August 2025, Cytokinetics presented new clinical data for aficamten at the European Society of Cardiology Congress in Madrid, with findings published in...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
Analyst ratings
82%
of 22 ratingsMore CYTK News
New insider activity at Cytokinetics ( (CYTK) ) has taken place on September 2, 2025. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50%...
H.C. Wainwright analyst Joseph Pantginis reiterates a Buy rating and $120 price target on Cytokinetics (CYTK) after the company hosted an investor event to disc...
Shares of Cytokinetics, Inc. CYTK are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety an...
James Condulis, an analyst from Stifel Nicolaus, maintained the Buy rating on Cytokinetics. The associated price target was raised to $96.00. Elevate Your Inves...
Cytokinetics (CYTK) announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, inc...